6 1. ABSTRACT Background: This study is primarily aimed at describing migraine illnesses, the existing patient care algorithm with this diagnosis and to estimate the direct costs of treatment of migraine from the point of view of the health care system in the Czech Republic. In the theoretical part, the basic concepts and procedures of health economics and the health technologies assessment are examined, especially the cost-of-illness of the analysis that is conducted in the practical part, namely just on the illness of migraine. Methods: The cost of drugs used to treat migraine is determined using FNHK (Fakultni nemocnice Hradec Kralove) prescription data. Further, using the data on health care (both ambulatory and inpatient care), these services are being appraised and this way the cost of treatment of a patient with the disease estimated from the point of view of the health system in the Czech Republic. Results: The average annual cost of treatment of one patient with episodic migraine was assessed at CZK 1,182 for outpatient care, CZK 786 for hospitalization and CZK 2,707 for medication. For chronic migraines, the average cost is higher and estimated at CZK 3,321 for outpatient care, CZK 2,745 for hospitalization and CZK 7,415 for medication. Conclusions: The total direct annual cost of the patient was...

Applying pharmacoeconomic methods were compared two selected treatments of depressive disorder. Markov model was created to evaluate cost-effectiveness of the two strategies. Knowledge from the clinical practice and the clinical research findings of the author are linked with pharmacoeconomic techniques into a multidisciplinary complex. The proposed sequential therapy uses a prediction of antidepressant response by utilizing of recent quantitative electroencephalography methods. Sequential therapy is more cost-effective compared with the conventional therapeutic strategy according to clinical guidelines. The results and limitations of the study are discussed at the conclusion from clinical and economic perspective.

No description available.

Objective: To evaluate the utilization and cost of drugs for the treatment of asthma and COPD in Lithuania in 2006-2009. Methodology: The data on the sales of drugs for asthma and COPD for the year 2006-2009 was obtained from SoftDent, JSC, database. The utilization of the R03 group (drugs for obstructive airway diseases) of the Anatomical Therapeutic Chemical (ATC) classification was analysed. The utilization was expressed as DDD/1000 inhabitants per day. The pharmacoeconomical analysis was performed implementing cost-minimisation and reference pricing methodologies. Results: The total use of drugs for asthma and COPD increased from 23,70 DDD/1000 inhabitants/day in 2006 to 28,67 DDD/1000 inhabitants/day in 2009. The most significant increase is found in the use of inhaled corticosteroid/long-acting β2-agonist combinations. The costs for drugs for the treatment of asthma and COPD increased from 59,71 million Litas in 2006 to 80,12 million Litas in 2008 and decreased to 79,25 million Litas in 2009. The use of drugs of the ATC group R03 is about 2 times higher in Norway, Denmark and Finland and about 1,6 times lower in Estonia. The pharmacoeconomical analysis shows marked savings if the lowest of the second lowest prices of one DDD were implemented as the reference price. The most considerable saving is found to be for inhaled corticosteroid/long-acting β2-agonist combinations – using the lowest basic price of one DDD as the reference price, total 18,04 million Litas would... [to full text] / Tikslas: Įvertinti vaistų, vartojamų astmai ir lėtinei obstrukcinei plaučių ligai (LOPL) gydyti suvartojimą ir išlaidas Lietuvoje 2006-2009 metais. Metodika: Duomenys apie vaistų, vartojamų astmai ir LOPL gydyti pardavimus 2006-2009 metais gauti iš UAB SoftDent duomenų bazės. Analizuojami vaistai yra klasifikuojami R03 grupėje (vaistai obstrukcinėms plaučių ligoms) pagal Anatominę Terapinę Cheminę (ATC) klasifikaciją. Vaistų suvartojimas išreikštas DDD skaičiumi, tenkančiu tūkstančiui gyventojų per vieną dieną. Farmakoekonominė analizė atlikta taikant kaštų mažinimo ir referentinės kainos metodus. Rezultatai: Bendras vaistų astmai ir LOPL gydyti suvartojimas Lietuvoje išaugo nuo 23,70 DDD/1000 gyventojų per dieną 2006 metais iki 28,67 DDD/1000 gyventojų per dieną 2009 metais. Didžiausias suvartojimo augimas nustatytas inhaliuojamų gliukokortikosteroidų/ilgo veikimo β2-agonistų kombinuotų preparatų grupėje. Išlaidos vaistų, vartojamų astmai ir LOPL gydyti augo nuo 59,71 mln. Litų 2006 metais iki 80,12 mln. Litų 2008 metais ir 2009 metais sumažėjo iki 79,25 mln. Litų. Vaistų, klasifikuojamų R03 grupėje pagal ATC klasifikaciją, suvartojimas Lietuvoje yra apie 2 kartus mažesnis nei Norvegijoje, Danijoje ir Suomijoje ir apie 1,6 karto didesnis nei Estijoje. Farmakoekonominė analizė pateikia ženklius galimo taupymo pavyzdžius, jei mažiausia ar antra mažiausia vieno DDD kaina būtų taikoma kaip referentinė kaina. Reikšmingiausi farmakoekonominės analizės rezultatai nustatyti... [toliau žr. visą tekstą]

Introduction: Atypical Antipsychotics (AAPs) are approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder. AAPs are commonly used off-label to treat depression, post-traumatic stress disorder and neuropsychiatric symptoms in dementia due to lack of alternative treatment options and treatment resistance. Concerns for off-label use arise since AAPs increase the risk of cardiovascular events and death. The objectives were 1) describe patterns of RU and costs among off-label AAPs users in a nationally representative population 2) identify prevalence of off-label use in the Medicare population 3) compare RU and costs between off-label AAPs users and non-users with mental health conditions in Medicare. Methods: For the first objective, the Medical Expenditure Panel Survey (MEPS) datasets were used. AAPs users greater than 18 years were identified in this cross-sectional study. Generalized Linear Models (GLM) were used to estimate costs among users and non-users after controlling for age sex, gender, insurance type, marriage status, income and comorbidity index. For the second and third objective, Medicare datasets were used to identify prevalence, RU, and costs of off-label use in Medicare beneficiaries 18 years and older. RU and costs between propensity score matched AAPs user and non-user cohorts were compared in a retrospective cohort study. Results: The adjusted odds of having an office-based outpatient (OR=2.47, 95%CI: 1.55-3.92) or inpatient (OR=1.63, 95%CI: 1.26-2.10) visit were significantly higher among off-label AAPs users. Adjusted office-based visit ($1,943 vs. $1,346), prescription ($4,153 vs. $1,252) and total ($10,694 vs. $4,823) costs were significantly higher among users (p<0.0001). Among Medicare beneficiaries, approximately 37% of AAPs users had no FDA approved diagnosis. The typical off-label user was a white 70-year-old male. Common off-label uses were depression, anxiety and neurotic disorders and dementia. Off-label AAPs users had significantly higher mental health outpatient ($461 vs $297), prescription ($2,349 vs $282) and total ($3,665 vs $1,297) costs per beneficiary than non-users. About 30% of AAPs users had at least one mental health outpatient visit during the year versus 23% of non-users; no significant differences were found in inpatient visits. AAPs non-users had significantly higher all-cause inpatient costs ($6,945 vs. $4,841) per beneficiary (p Conclusion: In a nationally representative population comprising a younger age group AAPs users had higher all-cause RU and total costs than non-users. Off-label prescribing of AAPs continued to be a prevalent practice affecting 37% of Medicare AAPs users. Off-label AAPs users had higher mental health costs but no significant differences in all-cause total health care costs in a Medicare population. Off-label use of AAPs can be a cost-effective option if future research shows off-label use is associated with increased effectiveness, which offsets any additional costs.

A gestão do processo saúde/doença tem requerido somas cada vez maiores de recursos especialmente àqueles destinados à aquisição de medicamentos em hospitais de porte especial, devido à complexidade dos procedimentos, incorporação de novas tecnologias, visando não só o acesso, mas, também a qualidade de vida da população assistida. Uma das estratégias possíveis para a minimização dos custos hospitalares com a aquisição de medicamentos é instalação de farmácia semi-industrial para a produção dos mesmos, após rigoroso estudo de viabilidade econômica. Neste contexto esta investigação teve como objetivo estabelecer estratégia de estudo farmacoeconômico para avaliar a viabilidade de implantação de farmácia semi-industrial para produção de medicamentos em hospital de porte especial da rede pública. Para tanto foi realizado um estudo do consumo e dos gastos hospitalares com medicamentos nos anos 2006/2007, visando conhecer as classes que aliassem maior consumo e valor monetário e seus requisitos para a manufatura. As formas farmacêuticas que despertaram maior expectativa de produção foram os medicamentos na forma sólida (comprimidos simples e revestidos), os injetáveis de pequeno volume e os pós liofilos injetáveis. Para estes foram planejadas as instalações (área física e equipamentos), matérias-primas e recursos humanos necessários para a produção. A análise de viabilidade farmacoeconômica foi realizada considerando valores médios para as formulações, incluindo excipiente e fármaco, custos de implantação e implementação. O estudo demonstrou que a produção hospitalar de medicamentos é viável sob o ponto de vista farmacoeconômico, pois o investimento se paga no primeiro mês e a partir deste passa a reduzir os gastos hospitalares com medicamentos, ou seja, começa a dar lucro e gerar benefícios para a sociedade. / The health/sickness process management has required greater sums of resources specially those destinated to medicines acquisition in special port hospital, due to complexity of proceeding, incorporation of new technology, having in view not only the access but, also the assisted population quality of life. One of the possible strategies for hospital cost minimization with medicines acquisition is the installation of a semi industrial pharmacy, to product these medicines, after an accurate of economic viability. In this context, this investigation aimed establish pharmacoeconomics study strategy to evaluate the implantation of semi industrial pharmacy for medicine production in special port hospital of the public service. For this a study of the consumption and the hospital expenses with medicine was realized in 2006/2007, having a view to know the classes that ally a greater consumption and monetary value and its requisite for manufacture. The pharmaceutic forms that excit a greater production expectative were the solid form medicines (simple and coated tablets), the injectables of small volumes, and injectable liofile powder. For this the necessary installations (physical area and equipments), raw material and human resources were planned for the production. The pharmacoeconomics viability analysis was realized considering medium values for the formulations including excipients and drug, implantation and implementation costs. The study has showed that the medicine hospital productions is viable under the pharmacoeconomics point of view because the investment is paid in a month and after that the hospital expenses with medicines are reduced, so its begins to give profit and benefits for the society.

The cancer treatment is, thanks to new technologies, very expensive, nowadays. According to demographic data and analysis the Czech population is aging, and it is highly probable that these costs will rise even more. Therefore it is necessary to look through pharmacoeconomic analyzes to find optimal solutions of treatment. The goal of this thesis is to clarify the concept of pharmacoeconomics, cancer and breast cancer. Through the use of demographic data the aim is to assess the status of cancer patients in the future, determine the amount of expenditures for the treatment of breast cancer I have used a model patient, suffering this disease, determine the amount and cost of the conventional and biological method of treatment.

Introdução: A expectativa global para 2030 é uma incidência de 26,4 milhões de casos e 17 milhões de mortes causadas pelo câncer. O câncer colorretal (CCR) já é terceiro tumor mais incidente no mundo. No Brasil, o CCR é o terceiro tumor mais incidente em homens e o segundo em mulheres na região sul. Neste cenário pessimista, é importante avaliar a relação entre o custo e o benefício de tecnologias para o tratamento quimioterápico, sobretudo na gestão dos gastos na saúde pública. Objetivo: O presente trabalho objetivou avaliar as alternativas para o CCR, XELOX e mFOLFOX6, sob o aspecto econômico. Metodologia: As informações sobre a efetividade foram obtidas através de uma revisão narrativa da literatura. Realizou-se também uma revisão narrativa de estudos farmacoeconômicos e por fim uma análise de custo minimização (ACM) sob a perspectiva de um hospital de caráter público. O microcusteio foi utilizado como método para estimar o custo de cada componente que incluiu medicamentos, materiais, exames laboratorial e de imagem, atendimentos ambulatoriais, diárias de internação e recursos humanos e administrativos, permitindo identificar o custo individual por paciente, com cada alternativa. O sistema informatizado do hospital foi utilizado para a coleta dos dados. Resultados: Foram encontrados 14 estudos farmacoeconômicos, dentre os quais apenas 2 estudos nacionais, ambos em cenário metastático da doença. A ACM revelou um custo por paciente de R$ 9.925,98 (adjuvância) e R$ 8.036,95 (paliativo) para mFOLFOX6, e R$ 8.407,13 (adjuvância) e R$ 6.946,47 (paliativo) para tratamento com XELOX. Os custos de materiais e medicamentos representam cerca de 85% do custo total de XELOX; para mFOLFOX6 esse custo é menor, em torno de 36%. Por outro lado, os custos com internação e colocação de cateter ocorrem exclusivamente para mFOLFOX6, que também apresenta maior custo com recursos humanos. Conclusão: O número de pacientes e a falta de dados no sistema informatizado da instituição reforçam a necessidade de mais estudos para se afirmar que XELOX é menos oneroso que mFOLFOX6 no sistema público. O estudo é inédito por se tratar de uma ACM utilizando o método de microcusteio para comparar as alternativas em um hospital público e universitário do país, especialmente na adjuvância do CCR. / Introduction: The global expectation for 2030 is an incidence of 26.4 million cases and 17 million deaths caused by cancer. Colorectal cancer (CRC) is already the third most incident tumor in the world. In Brazil, CRC is the third most incident tumor in men and the second in women in the southern region. In this pessimistic scenario, it is important to evaluate the relationship between the cost and the benefit of technologies for chemotherapy treatment, especially in the management of public health expenditures. Objective: The present study aimed to evaluate the alternatives for CRC, XELOX and mFOLFOX6, under the economic aspect. Methodology: Information on effectiveness was obtained through a narrative review of the literature. A narrative review of pharmacoeconomic studies was also conducted, and finally, a cost minimization analysis (CMA) from a public hospital perspective was carried out. The micro-costing was used as a method to estimate the cost of each component that included medicines, materials, laboratory and imaging exams, outpatient visits, hospital stay and human and administrative resources, allowing the individual cost per patient to be identified for each alternative. The computerized system of the hospital was used to collect the data. Results: We found 14 pharmacoeconomic studies, of which only 2 national studies, both in the metastatic setting of the disease. The CMA revealed a cost per patient of BRL$ 9,925.98 (adjuvant) and BRL$ 8,036.95 (palliative) for mFOLFOX6, and BRL$ 8,407.13 (adjuvant) and BRL$ 6,946.47 (palliative) for treatment with XELOX. Material and drug costs account for about 85% of the total cost of XELOX; For mFOLFOX6 this cost is lower, around 36%. On the other hand, costs with hospitalization and catheter placement occur exclusively for mFOLFOX6, which also presents higher cost with human resources. Conclusion: The number of patients and the lack of data in the computerized system of the institution reinforce the need for further studies to assert that XELOX is less costly than mFOLFOX6 in the public system. The study is notorious because it is a CMA using the micro-costing method to compare the alternatives in a public and university hospital in the country, especially in the adjuvant treatment of CRC.

No description available.

Introduction: Prescription drug monitoring programs (PDMPs) are one strategy established to curb the prescription opioid abuse epidemic. Prescriber use mandates has emerged as a promising practice to increase PDMPs impact on prescription opioid abuse; however, evidence of its effectiveness has not yet been established. Kentucky was the first state to implement comprehensive prescriber use mandates in July 2012. Objective: To assess the relationship between prescriber use mandates policy and emergency department (ED) visits related to prescription opioid poisoning among adults in Kentucky and North Carolina. Secondary aim: to evaluate the economic impact of prescriber use mandates in Kentucky. Methods: A controlled, pre-post study design. Data from the State Emergency Department Databases (SEDD) and the State Inpatient databases (SID) were used to identify prescription opioid poisoning ED visits among those ≥ 12 years old. Prevalence rate were estimated. Prescription opioid poisoning ED visits were characterized based on sociodemographic and clinical characteristics. Logistic regression was applied to compare occurrences of prescription opioid poisoning ED visits pre and post prescriber use mandates in Kentucky, and between Kentucky and North Carolina for the period 2011 to 2014. A cost of illness framework was applied to estimate direct medical costs associated with prescription opioid poisoning ED visits. The economic impact of prescriber use mandates was quantified based on logistic regression coefficient for the interaction term (state*time to implementation). Results: There were 7,419 and 12,598 prescription opioid poisoning -related ED visits in Kentucky and North Carolina, respectively. Young and Middle age, male gender, white, having one or more chronic conditions, and psychiatric conditions (such as depression and drug abuse) were significantly associated with prescription opioid poisoning ED visits (p-value<0.05). The odds of having a prescription opioid poisoning ED visit in Kentucky were significantly lower compared to North Carolina in 2012, 2013, and 2014 compared to 2011 (OR = 0.9, 0.7, and 0.7 respectively). The total estimated direct medical costs were $13.77 and $24.37 million in Kentucky and North Carolina, respectively. In Kentucky, the economic impact of prescriber use mandates was estimated at - $2.3 million. Conclusion: Prescriber use mandates is effective in reducing prescription opioid poisoning ED visits, and its economic impact is considerable.